Biocardia Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Biocardia Stock Summary

Biocardia competes with Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, Rezolute, and AN2 Therapeutics. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.

Biocardia Key Financial Ratios

Biocardia Key Balance Sheet Accounts

Biocardia Key Cash Accounts

Biocardia Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biocardia's current stock value. Our valuation model uses many indicators to compare Biocardia value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biocardia competition to find correlations between indicators driving Biocardia's intrinsic value. More Info.Biocardia is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Biocardia's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biocardia's earnings, one of the primary drivers of an investment's value.

Biocardia Systematic Risk

Today, most investors in Biocardia Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biocardia's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biocardia growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Biocardia help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biocardia. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biocardia based on widely used predictive technical indicators. In general, we focus on analyzing Biocardia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biocardia's daily price indicators and compare them against related drivers.

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.